Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.36 |
| ▸ | IGF2R | P11717 | 4/20 | 0.32 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.32 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20334736 | 0.88 | — | — | |
| SCHEMBL23984435 | 0.86 | FBP1 (0.34) | FBP1LGALS8IGF2R | |
| SCHEMBL14592737 | 0.82 | FBP1 (0.44) | FBP1IGF2RAMDHD2 | |
| SCHEMBL26474225 | 0.81 | — | — | |
| SCHEMBL24211093 | 0.81 | — | — | |
| SCHEMBL20329196 | 0.81 | — | — | |
| SCHEMBL15293066 | 0.80 | FBP1 (0.59) | FBP1IGF2RAMDHD2 | |
| SCHEMBL14928402 | 0.80 | FBP1 (0.59) | FBP1IGF2RAMDHD2 | |
| SCHEMBL18844825 | 0.80 | FBP1 (0.59) | FBP1IGF2RAMDHD2 | |
| SCHEMBL17789075 | 0.80 | FBP1 (0.59) | FBP1IGF2RAMDHD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200377886-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377886-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, RBM17 | FBP1 3177/4885LGALS8 2367/4885IGF2R 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.